Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd., commonly referred to as Glenmark, is a prominent global player in the pharmaceutical industry, headquartered in Mumbai, India. Founded in 1977, the company has established a strong presence in over 80 countries, with significant operations in North America, Europe, and emerging markets. Specialising in the development of branded generics, specialty pharmaceuticals, and over-the-counter products, Glenmark is recognised for its innovative approach to drug development, particularly in the fields of dermatology, oncology, and respiratory care. The company has achieved notable milestones, including a robust pipeline of new chemical entities and a strong portfolio of generic medications. With a commitment to quality and research, Glenmark Pharmaceuticals has positioned itself as a leader in the industry, earning accolades for its contributions to healthcare and patient well-being.
DitchCarbon Score
How does Glenmark Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Pharmaceuticals's score of 55 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Glenmark Pharmaceuticals's reported carbon emissions
In 2023, Glenmark Pharmaceuticals reported total greenhouse gas emissions of approximately 127,980 tonnes CO2e for Scope 1, 50,407 tonnes CO2e for Scope 2, and a significant 175,069,000 tonnes CO2e for Scope 3 emissions. This reflects a continued commitment to addressing climate change within their operations. Glenmark has set ambitious targets to reduce its carbon footprint, committing to a 35% reduction in absolute Scope 1 and 2 emissions by FY2035, using FY2021 as the baseline year. Additionally, the company aims to decrease Scope 3 emissions—specifically from purchased goods and services, fuel and energy-related activities, downstream transportation and distribution, and investments—by 28% per tonne of pharmaceutical products within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are classified as consistent with the goal of limiting global warming to well below 2°C. Glenmark's proactive approach demonstrates its dedication to sustainability and reducing its environmental impact in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 11,713,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 74,231,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,277,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glenmark Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
